Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Basel, 29. Dezember 2016 - Basilea Pharmaceutica AG (SIX: BSLN) teilte heute mit, dass Ursula Eberhardt ab dem 1. Januar 2017 die Leitung von Basileas Personalabteilung übernimmt sowie Mitglied...
-
Basel, Switzerland, December 29, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of January 1, 2017, Ursula Eberhardt will take the role of Head of Global Human Resources and...
-
Liestal, Switzerland, December 23, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that it has been informed that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) designated...
-
Liestal, Schweiz, 23. Dezember 2016 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass die britische Arzneimittelbehörde MHRA (Medicines and Healthcare Products Regulatory Agency) Raxone®...
-
Kuntarahoitus Oyj Pörssitiedote 22.12.2016 klo 8.00 Moody's vahvisti Kuntarahoituksen Aa1-luottoluokituksen Luottoluokituslaitos Moody's vahvisti 21.12.2016 Kuntarahoituksen pitkäaikaisen...
-
Municipality Finance Plc Stock exchange release 22 December 2016, 08:00 EET Moody's affirms Municipality Finance Plc's Aa1 credit rating The credit rating agency Moody's affirmed its long-term...
-
ALLSCHWIL, SWITZERLAND - 21 December 2016 - Actelion (SIX: ATLN) has entered into exclusive negotiations with Johnson & Johnson regarding a possible strategic transaction. There can be no...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Approximately one year after its national...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Rund ein Jahr nach der Gründung der...
-
Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc. to add first-in-class disease modifying topical treatment for presbyopia...